{"id":18925,"date":"2023-12-21T18:34:19","date_gmt":"2023-12-21T13:04:19","guid":{"rendered":"https:\/\/www.fintoo.in\/blog\/?p=18925"},"modified":"2023-12-21T18:34:20","modified_gmt":"2023-12-21T13:04:20","slug":"innova-captab-limited-subscribe","status":"publish","type":"post","link":"https:\/\/blog.fintoo.in\/blog\/innova-captab-limited-subscribe\/","title":{"rendered":"\u00a0\u00a0\u00a0 Innova Captab Limited (Subscribe)"},"content":{"rendered":"\n

Highlights<\/h2>\n\n\n\n
Issue Size \u2013: 12,723,785 shares<\/td>Issue Open\/Close \u2013 21 Dec \/ 26 Dec, 2023<\/td><\/tr>
Price Band (Rs.) \u00a0426 \u2013 448<\/td>Issue Size (Rs.) \u2013 5,700 mn<\/td><\/tr>
Face Value (Rs) 10<\/td>Lot Size (shares) 33<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Innova Captab Limited (ICL) was incoprporated as Harun Health Care Private Limited in 2005 and later changed their name to Innova Captab Private Limited in 2010 in order to reflect innovations in the pharmaceutical sector. The company is an integrated pharmaceutical company in India with a presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports.<\/p>\n\n\n\n

ICL business includes (i) a contract development and manufacturing organization (CDMO) business providing manufacturing services to Indian pharmaceutical companies, (ii) a domestic branded generics business and (iii) an international branded generics business.<\/p>\n\n\n\n

According to the Crisil\u2019s report the company have recorded the third highest operating revenue, the second highest operating profit margin, the third highest net profit margin and the second highest return on capital employed among Indian formulation CDMO players in FY22.<\/p>\n\n\n\n

In FY23 and in the Q1FY2024, they have manufactured a diverse generics product portfolio of over 600 products and market them under their own brands in the Indian market through a developed network of approximately 5,000 distributors and stockists and over 150,000 retail pharmacies.<\/p>\n\n\n\n

In ICL\u2019s CDMO business, they have developed relationships across the Indian pharmaceutical industry. Some of thier key customers include Cipla Limited, Glenmark Pharmaceuticals Limited, Wockhardt Limited, Corona Remedies Private Limited, Emcure Pharmaceuticals Limited, Lupin Limited, Intas Pharmaceuticals Limited, Leeford Healthcare Limited etc.<\/p>\n\n\n\n

Out of the total proceeds of Rs. 5,700 mn, Rs. 1,440 mn would go towards repayment and \/ or prepayment, in part or in full, of certain outstanding loans of the company, Rs. 236 mn would go towards Investment in their Subsidiary, UML, for repayment or prepayment in part or full of outstanding loans availed by UML, Rs. 720 mn would go towards funding working capital requirements and Rs. 2,500 mn would go towards existing selling shareholders of the company.<\/p>\n\n\n\n

Key Highlights<\/h2>\n\n\n\n